European Training Network for innovative drug development strategies and regulatory tools
PEARRL is a European Training Network (ETN) funded under the Horizon 2020 Marie Sklodowska-Curie actions. It brings together European Pharma industry, academia and regulatory agency partners in a multisectorial team to deliver a unique research and training programme for 15 Early Stage Researchers (ESR).
The main research objectives of the PEARRL research programme are to deliver novel bio-enabling formulations and new biopharmaceutics tools to predict their in vivo performance as a means to improve efficiency and cost-competitiveness in drug development, thus facilitating earlier access of patients to “breakthrough therapies”.
PEARRL will train 15 Early Stage Researchers (ESR) who can develop such new bio-enabling formulations (“better drugs”), biorelevant and in silico methods to predict formulation performance in vivo (“streamlined development”) and serve as communication bridgers between research and regulatory science (“accelerated approval”), thus bringing Pharma and regulatory objectives to fruition.
The members of the PEARRL consortium have been carefully selected to bring together a multi-disciplinary, multisectorial and multi-national network that offers the best response to the scientific, economic and societal challenges outlined in Section 2. Our network consists of 9 Beneficiaries and 9 Partner Organisations from 8 different countries. The Consortium covers the entire chain of knowledge, i.e. development and training from the laboratory to the end-user and market.
The sectors involved in PEARRL
The unique collaboration of leaders in Europe`s Pharma industry and academic excellence together with four of the most influential regulatory authorities in Europe; all with expertise working with innovative drug formulations and biopharmaceutics tools